Developing stable lentiviral vector producer cell lines is a time-consuming and labor-intensive process, often taking a year or more to fully develop and characterize the cell line development platform. Due to the complexity of the work, many market-available systems ultimately fail to meet the needs of commercial manufacturing due to issues such as toxigenic titer, cell line stability, and culture adaptation.
EurekaBio has developed its proprietary EuLV® system, which can deliver stable LVV HEK293T producer cell lines in as short a time period as 5 months. The EuLV® system has irreplaceable advantages in terms of process reliability, scale-up capability, production cost, and virus product safety. The potential to achieve high-titer lentiviral vector manufacture using this platform will be explored in this webinar using a real-world case study.
Join us for a webinar on ways to address the pressing need for a reliable and scalable lentiviral vector manufacturing solution.